Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29861524 | 1.00 | ADORA3 (0.44) | ADORA3MLYCDDYRK1AADORA2APTPN5 | |
| SCHEMBL29910346 | 0.82 | ADORA3 (0.49) | ADORA3DYRK1AADORA2APTPN5KDM4E | |
| SCHEMBL23326908 | 0.82 | ADORA3 (0.49) | ADORA3DYRK1AADORA2APTPN5KDM4E | |
| SCHEMBL23326649 | 0.81 | ADORA3 (0.52) | ADORA3DYRK1AADORA2APTPN5KDM4E | |
| SCHEMBL30638959 | 0.80 | MLYCD (0.41) | MLYCDDYRK1A | |
| SCHEMBL6867485 | 0.75 | ADORA3 (0.43) | ADORA3ADORA2ACYP1A2MAPK8MAPK9 | |
| SCHEMBL28655727 | 0.74 | MLYCD (0.45) | MLYCDLMNAGPR35NR2E1 | |
| SCHEMBL23326784 | 0.73 | PTPN5 (0.44) | MLYCDPTPN5KDM4EGPR35CYP1A2 | |
| SCHEMBL29861148 | 0.73 | PTPN5 (0.44) | MLYCDPTPN5KDM4EGPR35CYP1A2 | |
| SCHEMBL3652937 | 0.70 | MLYCD (0.55) | MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4620531-A2 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| CN-116425742-A | Bicyclic heteroaryl compounds and uses thereof | 锐新医药公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4055017-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114901662-A | Bicyclic heteroaryl compounds and uses thereof | 锐新医药公司 | 2022-08-12 | — | — | CN | disclosed |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | ADORA3 3386/4885MLYCD 2823/4885DYRK1A 1861/4885 |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | ADORA3 2206/4885MLYCD 1328/4885DYRK1A 2337/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | ADORA3 2206/4885MLYCD 1328/4885DYRK1A 2337/4885 |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | SOST, SOS1, SOS2 | ADORA3 2206/4885MLYCD 1328/4885DYRK1A 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.